Global Imipenem and Cilastatin Injection Market Growth 2026-2032
The global Imipenem and Cilastatin Injection market size is predicted to grow from US$ 444 million in 2025 to US$ 586 million in 2032; it is expected to grow at a CAGR of 4.0% from 2026 to 2032.
Imipenem and Cilastatin Injection is a carbapenem combination antibiotic supplied as a ready-to-use or reconstituted injectable solution. By combining imipenem with cilastatin at a fixed ratio, it preserves strong antibacterial activity against Gram-negative, Gram-positive, and anaerobic pathogens while reducing renal metabolism of the active component. It is widely used for severe pneumonia, sepsis, complicated intra-abdominal infections, complicated skin and soft tissue infections, and serious hospital-acquired infections associated with multidrug-resistant bacteria. The upstream supply chain mainly includes pharmaceutical-grade beta-lactam core structures and key side-chain intermediates, cilastatin raw material, solvents and stabilizing systems for injectable solutions, aseptic filling consumables and packaging materials, as well as GMP-compliant aseptic compounding, filling, and testing equipment, all of which require stringent control over process consistency, impurity profiles, and sterility assurance. Downstream customers primarily consist of general hospitals, tertiary hospitals, regional medical centers, and selected specialty hospitals, with utilization driven through centralized hospital procurement and reimbursement systems. Based on ex-factory pricing, global nominal production capacity of imipenem and cilastatin injection in 2025 is estimated at approximately 56.0 million units, with actual sales volume of around 43.65 million units and an average global ex-factory price of about USD 10.4 per unit. Constrained by technical barriers in sterile injectable manufacturing, intensive quality system requirements, and sustained pricing pressure from hospital tenders, leading manufacturers typically achieve gross margins in the range of 42%–58%, reflecting a mature market characterized by stable demand, competitive dynamics, and scale- and compliance-driven profitability.
United States market for Imipenem and Cilastatin Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Imipenem and Cilastatin Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Imipenem and Cilastatin Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Imipenem and Cilastatin Injection players cover Merck, Fresenius, Venus Remedies, Sun Pharmaceutical, JW Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Imipenem and Cilastatin Injection Industry Forecast” looks at past sales and reviews total world Imipenem and Cilastatin Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Imipenem and Cilastatin Injection sales for 2026 through 2032. With Imipenem and Cilastatin Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Imipenem and Cilastatin Injection industry.
This Insight Report provides a comprehensive analysis of the global Imipenem and Cilastatin Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Imipenem and Cilastatin Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Imipenem and Cilastatin Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Imipenem and Cilastatin Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Imipenem and Cilastatin Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Imipenem and Cilastatin Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Imipenem and Cilastatin Injection market?
What factors are driving Imipenem and Cilastatin Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Imipenem and Cilastatin Injection market opportunities vary by end market size?
How does Imipenem and Cilastatin Injection break out by Type, by Application?
Imipenem and Cilastatin Injection is a carbapenem combination antibiotic supplied as a ready-to-use or reconstituted injectable solution. By combining imipenem with cilastatin at a fixed ratio, it preserves strong antibacterial activity against Gram-negative, Gram-positive, and anaerobic pathogens while reducing renal metabolism of the active component. It is widely used for severe pneumonia, sepsis, complicated intra-abdominal infections, complicated skin and soft tissue infections, and serious hospital-acquired infections associated with multidrug-resistant bacteria. The upstream supply chain mainly includes pharmaceutical-grade beta-lactam core structures and key side-chain intermediates, cilastatin raw material, solvents and stabilizing systems for injectable solutions, aseptic filling consumables and packaging materials, as well as GMP-compliant aseptic compounding, filling, and testing equipment, all of which require stringent control over process consistency, impurity profiles, and sterility assurance. Downstream customers primarily consist of general hospitals, tertiary hospitals, regional medical centers, and selected specialty hospitals, with utilization driven through centralized hospital procurement and reimbursement systems. Based on ex-factory pricing, global nominal production capacity of imipenem and cilastatin injection in 2025 is estimated at approximately 56.0 million units, with actual sales volume of around 43.65 million units and an average global ex-factory price of about USD 10.4 per unit. Constrained by technical barriers in sterile injectable manufacturing, intensive quality system requirements, and sustained pricing pressure from hospital tenders, leading manufacturers typically achieve gross margins in the range of 42%–58%, reflecting a mature market characterized by stable demand, competitive dynamics, and scale- and compliance-driven profitability.
United States market for Imipenem and Cilastatin Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Imipenem and Cilastatin Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Imipenem and Cilastatin Injection is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Imipenem and Cilastatin Injection players cover Merck, Fresenius, Venus Remedies, Sun Pharmaceutical, JW Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Imipenem and Cilastatin Injection Industry Forecast” looks at past sales and reviews total world Imipenem and Cilastatin Injection sales in 2025, providing a comprehensive analysis by region and market sector of projected Imipenem and Cilastatin Injection sales for 2026 through 2032. With Imipenem and Cilastatin Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Imipenem and Cilastatin Injection industry.
This Insight Report provides a comprehensive analysis of the global Imipenem and Cilastatin Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Imipenem and Cilastatin Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Imipenem and Cilastatin Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Imipenem and Cilastatin Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Imipenem and Cilastatin Injection.
This report presents a comprehensive overview, market shares, and growth opportunities of Imipenem and Cilastatin Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 0.5g
- 1.0g
- 2.0g
- Severe Hospital-acquired Infections
- Multidrug-resistant Bacterial Infections
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- Fresenius
- Venus Remedies
- Sun Pharmaceutical
- JW Pharmaceutical
- Taiwan Biotech
- Zhuhai United Laboratories
- Hanhui Pharmaceuticals
What is the 10-year outlook for the global Imipenem and Cilastatin Injection market?
What factors are driving Imipenem and Cilastatin Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Imipenem and Cilastatin Injection market opportunities vary by end market size?
How does Imipenem and Cilastatin Injection break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Imipenem and Cilastatin Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Imipenem and Cilastatin Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Imipenem and Cilastatin Injection by Country/Region, 2021, 2025 & 2032
2.2 Imipenem and Cilastatin Injection Segment by Type
2.2.1 0.5g
2.2.2 1.0g
2.2.3 2.0g
2.2.4 Imipenem and Cilastatin Injection Sales by Type
2.2.4.1 Global Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
2.2.4.2 Global Imipenem and Cilastatin Injection Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Imipenem and Cilastatin Injection Sale Price by Type (2021-2026)
2.3 Imipenem and Cilastatin Injection Segment by Clinical Indication
2.3.1 Severe Hospital-acquired Infections
2.3.2 Multidrug-resistant Bacterial Infections
2.3.3 Others
2.3.4 Imipenem and Cilastatin Injection Sales by Clinical Indication
2.3.4.1 Global Imipenem and Cilastatin Injection Sales Market Share by Clinical Indication (2021-2026)
2.3.4.2 Global Imipenem and Cilastatin Injection Revenue and Market Share by Clinical Indication (2021-2026)
2.3.4.3 Global Imipenem and Cilastatin Injection Sale Price by Clinical Indication (2021-2026)
2.4 Imipenem and Cilastatin Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.4.4 Imipenem and Cilastatin Injection Sales by Application
2.4.4.1 Global Imipenem and Cilastatin Injection Sale Market Share by Application (2021-2026)
2.4.4.2 Global Imipenem and Cilastatin Injection Revenue and Market Share by Application (2021-2026)
2.4.4.3 Global Imipenem and Cilastatin Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Imipenem and Cilastatin Injection Breakdown Data by Company
3.1.1 Global Imipenem and Cilastatin Injection Annual Sales by Company (2021-2026)
3.1.2 Global Imipenem and Cilastatin Injection Sales Market Share by Company (2021-2026)
3.2 Global Imipenem and Cilastatin Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Imipenem and Cilastatin Injection Revenue by Company (2021-2026)
3.2.2 Global Imipenem and Cilastatin Injection Revenue Market Share by Company (2021-2026)
3.3 Global Imipenem and Cilastatin Injection Sale Price by Company
3.4 Key Manufacturers Imipenem and Cilastatin Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Imipenem and Cilastatin Injection Product Location Distribution
3.4.2 Players Imipenem and Cilastatin Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IMIPENEM AND CILASTATIN INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Imipenem and Cilastatin Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Imipenem and Cilastatin Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Imipenem and Cilastatin Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Imipenem and Cilastatin Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Imipenem and Cilastatin Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Imipenem and Cilastatin Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Imipenem and Cilastatin Injection Sales Growth
4.4 APAC Imipenem and Cilastatin Injection Sales Growth
4.5 Europe Imipenem and Cilastatin Injection Sales Growth
4.6 Middle East & Africa Imipenem and Cilastatin Injection Sales Growth
5 AMERICAS
5.1 Americas Imipenem and Cilastatin Injection Sales by Country
5.1.1 Americas Imipenem and Cilastatin Injection Sales by Country (2021-2026)
5.1.2 Americas Imipenem and Cilastatin Injection Revenue by Country (2021-2026)
5.2 Americas Imipenem and Cilastatin Injection Sales by Type (2021-2026)
5.3 Americas Imipenem and Cilastatin Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Imipenem and Cilastatin Injection Sales by Region
6.1.1 APAC Imipenem and Cilastatin Injection Sales by Region (2021-2026)
6.1.2 APAC Imipenem and Cilastatin Injection Revenue by Region (2021-2026)
6.2 APAC Imipenem and Cilastatin Injection Sales by Type (2021-2026)
6.3 APAC Imipenem and Cilastatin Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Imipenem and Cilastatin Injection by Country
7.1.1 Europe Imipenem and Cilastatin Injection Sales by Country (2021-2026)
7.1.2 Europe Imipenem and Cilastatin Injection Revenue by Country (2021-2026)
7.2 Europe Imipenem and Cilastatin Injection Sales by Type (2021-2026)
7.3 Europe Imipenem and Cilastatin Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Imipenem and Cilastatin Injection by Country
8.1.1 Middle East & Africa Imipenem and Cilastatin Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Imipenem and Cilastatin Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Imipenem and Cilastatin Injection Sales by Type (2021-2026)
8.3 Middle East & Africa Imipenem and Cilastatin Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Imipenem and Cilastatin Injection
10.3 Manufacturing Process Analysis of Imipenem and Cilastatin Injection
10.4 Industry Chain Structure of Imipenem and Cilastatin Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Imipenem and Cilastatin Injection Distributors
11.3 Imipenem and Cilastatin Injection Customer
12 WORLD FORECAST REVIEW FOR IMIPENEM AND CILASTATIN INJECTION BY GEOGRAPHIC REGION
12.1 Global Imipenem and Cilastatin Injection Market Size Forecast by Region
12.1.1 Global Imipenem and Cilastatin Injection Forecast by Region (2027-2032)
12.1.2 Global Imipenem and Cilastatin Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Imipenem and Cilastatin Injection Forecast by Type (2027-2032)
12.7 Global Imipenem and Cilastatin Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.1.3 Merck Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Fresenius
13.2.1 Fresenius Company Information
13.2.2 Fresenius Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.2.3 Fresenius Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Fresenius Main Business Overview
13.2.5 Fresenius Latest Developments
13.3 Venus Remedies
13.3.1 Venus Remedies Company Information
13.3.2 Venus Remedies Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.3.3 Venus Remedies Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Venus Remedies Main Business Overview
13.3.5 Venus Remedies Latest Developments
13.4 Sun Pharmaceutical
13.4.1 Sun Pharmaceutical Company Information
13.4.2 Sun Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sun Pharmaceutical Main Business Overview
13.4.5 Sun Pharmaceutical Latest Developments
13.5 JW Pharmaceutical
13.5.1 JW Pharmaceutical Company Information
13.5.2 JW Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.5.3 JW Pharmaceutical Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 JW Pharmaceutical Main Business Overview
13.5.5 JW Pharmaceutical Latest Developments
13.6 Taiwan Biotech
13.6.1 Taiwan Biotech Company Information
13.6.2 Taiwan Biotech Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.6.3 Taiwan Biotech Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Taiwan Biotech Main Business Overview
13.6.5 Taiwan Biotech Latest Developments
13.7 Zhuhai United Laboratories
13.7.1 Zhuhai United Laboratories Company Information
13.7.2 Zhuhai United Laboratories Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.7.3 Zhuhai United Laboratories Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Zhuhai United Laboratories Main Business Overview
13.7.5 Zhuhai United Laboratories Latest Developments
13.8 Hanhui Pharmaceuticals
13.8.1 Hanhui Pharmaceuticals Company Information
13.8.2 Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.8.3 Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hanhui Pharmaceuticals Main Business Overview
13.8.5 Hanhui Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Imipenem and Cilastatin Injection Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Imipenem and Cilastatin Injection by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Imipenem and Cilastatin Injection by Country/Region, 2021, 2025 & 2032
2.2 Imipenem and Cilastatin Injection Segment by Type
2.2.1 0.5g
2.2.2 1.0g
2.2.3 2.0g
2.2.4 Imipenem and Cilastatin Injection Sales by Type
2.2.4.1 Global Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
2.2.4.2 Global Imipenem and Cilastatin Injection Revenue and Market Share by Type (2021-2026)
2.2.4.3 Global Imipenem and Cilastatin Injection Sale Price by Type (2021-2026)
2.3 Imipenem and Cilastatin Injection Segment by Clinical Indication
2.3.1 Severe Hospital-acquired Infections
2.3.2 Multidrug-resistant Bacterial Infections
2.3.3 Others
2.3.4 Imipenem and Cilastatin Injection Sales by Clinical Indication
2.3.4.1 Global Imipenem and Cilastatin Injection Sales Market Share by Clinical Indication (2021-2026)
2.3.4.2 Global Imipenem and Cilastatin Injection Revenue and Market Share by Clinical Indication (2021-2026)
2.3.4.3 Global Imipenem and Cilastatin Injection Sale Price by Clinical Indication (2021-2026)
2.4 Imipenem and Cilastatin Injection Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.4.4 Imipenem and Cilastatin Injection Sales by Application
2.4.4.1 Global Imipenem and Cilastatin Injection Sale Market Share by Application (2021-2026)
2.4.4.2 Global Imipenem and Cilastatin Injection Revenue and Market Share by Application (2021-2026)
2.4.4.3 Global Imipenem and Cilastatin Injection Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Imipenem and Cilastatin Injection Breakdown Data by Company
3.1.1 Global Imipenem and Cilastatin Injection Annual Sales by Company (2021-2026)
3.1.2 Global Imipenem and Cilastatin Injection Sales Market Share by Company (2021-2026)
3.2 Global Imipenem and Cilastatin Injection Annual Revenue by Company (2021-2026)
3.2.1 Global Imipenem and Cilastatin Injection Revenue by Company (2021-2026)
3.2.2 Global Imipenem and Cilastatin Injection Revenue Market Share by Company (2021-2026)
3.3 Global Imipenem and Cilastatin Injection Sale Price by Company
3.4 Key Manufacturers Imipenem and Cilastatin Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Imipenem and Cilastatin Injection Product Location Distribution
3.4.2 Players Imipenem and Cilastatin Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR IMIPENEM AND CILASTATIN INJECTION BY GEOGRAPHIC REGION
4.1 World Historic Imipenem and Cilastatin Injection Market Size by Geographic Region (2021-2026)
4.1.1 Global Imipenem and Cilastatin Injection Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Imipenem and Cilastatin Injection Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Imipenem and Cilastatin Injection Market Size by Country/Region (2021-2026)
4.2.1 Global Imipenem and Cilastatin Injection Annual Sales by Country/Region (2021-2026)
4.2.2 Global Imipenem and Cilastatin Injection Annual Revenue by Country/Region (2021-2026)
4.3 Americas Imipenem and Cilastatin Injection Sales Growth
4.4 APAC Imipenem and Cilastatin Injection Sales Growth
4.5 Europe Imipenem and Cilastatin Injection Sales Growth
4.6 Middle East & Africa Imipenem and Cilastatin Injection Sales Growth
5 AMERICAS
5.1 Americas Imipenem and Cilastatin Injection Sales by Country
5.1.1 Americas Imipenem and Cilastatin Injection Sales by Country (2021-2026)
5.1.2 Americas Imipenem and Cilastatin Injection Revenue by Country (2021-2026)
5.2 Americas Imipenem and Cilastatin Injection Sales by Type (2021-2026)
5.3 Americas Imipenem and Cilastatin Injection Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Imipenem and Cilastatin Injection Sales by Region
6.1.1 APAC Imipenem and Cilastatin Injection Sales by Region (2021-2026)
6.1.2 APAC Imipenem and Cilastatin Injection Revenue by Region (2021-2026)
6.2 APAC Imipenem and Cilastatin Injection Sales by Type (2021-2026)
6.3 APAC Imipenem and Cilastatin Injection Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Imipenem and Cilastatin Injection by Country
7.1.1 Europe Imipenem and Cilastatin Injection Sales by Country (2021-2026)
7.1.2 Europe Imipenem and Cilastatin Injection Revenue by Country (2021-2026)
7.2 Europe Imipenem and Cilastatin Injection Sales by Type (2021-2026)
7.3 Europe Imipenem and Cilastatin Injection Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Imipenem and Cilastatin Injection by Country
8.1.1 Middle East & Africa Imipenem and Cilastatin Injection Sales by Country (2021-2026)
8.1.2 Middle East & Africa Imipenem and Cilastatin Injection Revenue by Country (2021-2026)
8.2 Middle East & Africa Imipenem and Cilastatin Injection Sales by Type (2021-2026)
8.3 Middle East & Africa Imipenem and Cilastatin Injection Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Imipenem and Cilastatin Injection
10.3 Manufacturing Process Analysis of Imipenem and Cilastatin Injection
10.4 Industry Chain Structure of Imipenem and Cilastatin Injection
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Imipenem and Cilastatin Injection Distributors
11.3 Imipenem and Cilastatin Injection Customer
12 WORLD FORECAST REVIEW FOR IMIPENEM AND CILASTATIN INJECTION BY GEOGRAPHIC REGION
12.1 Global Imipenem and Cilastatin Injection Market Size Forecast by Region
12.1.1 Global Imipenem and Cilastatin Injection Forecast by Region (2027-2032)
12.1.2 Global Imipenem and Cilastatin Injection Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Imipenem and Cilastatin Injection Forecast by Type (2027-2032)
12.7 Global Imipenem and Cilastatin Injection Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.1.3 Merck Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Fresenius
13.2.1 Fresenius Company Information
13.2.2 Fresenius Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.2.3 Fresenius Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Fresenius Main Business Overview
13.2.5 Fresenius Latest Developments
13.3 Venus Remedies
13.3.1 Venus Remedies Company Information
13.3.2 Venus Remedies Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.3.3 Venus Remedies Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Venus Remedies Main Business Overview
13.3.5 Venus Remedies Latest Developments
13.4 Sun Pharmaceutical
13.4.1 Sun Pharmaceutical Company Information
13.4.2 Sun Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.4.3 Sun Pharmaceutical Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Sun Pharmaceutical Main Business Overview
13.4.5 Sun Pharmaceutical Latest Developments
13.5 JW Pharmaceutical
13.5.1 JW Pharmaceutical Company Information
13.5.2 JW Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.5.3 JW Pharmaceutical Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 JW Pharmaceutical Main Business Overview
13.5.5 JW Pharmaceutical Latest Developments
13.6 Taiwan Biotech
13.6.1 Taiwan Biotech Company Information
13.6.2 Taiwan Biotech Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.6.3 Taiwan Biotech Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Taiwan Biotech Main Business Overview
13.6.5 Taiwan Biotech Latest Developments
13.7 Zhuhai United Laboratories
13.7.1 Zhuhai United Laboratories Company Information
13.7.2 Zhuhai United Laboratories Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.7.3 Zhuhai United Laboratories Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Zhuhai United Laboratories Main Business Overview
13.7.5 Zhuhai United Laboratories Latest Developments
13.8 Hanhui Pharmaceuticals
13.8.1 Hanhui Pharmaceuticals Company Information
13.8.2 Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Product Portfolios and Specifications
13.8.3 Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hanhui Pharmaceuticals Main Business Overview
13.8.5 Hanhui Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Imipenem and Cilastatin Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Imipenem and Cilastatin Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 0.5g
Table 4. Major Players of 1.0g
Table 5. Major Players of 2.0g
Table 6. Global Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 7. Global Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Table 8. Global Imipenem and Cilastatin Injection Revenue by Type (2021-2026) & ($ million)
Table 9. Global Imipenem and Cilastatin Injection Revenue Market Share by Type (2021-2026)
Table 10. Global Imipenem and Cilastatin Injection Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Severe Hospital-acquired Infections
Table 12. Major Players of Multidrug-resistant Bacterial Infections
Table 13. Major Players of Others
Table 14. Global Imipenem and Cilastatin Injection Sales by Clinical Indication (2021-2026) & (K Units)
Table 15. Global Imipenem and Cilastatin Injection Sales Market Share by Clinical Indication (2021-2026)
Table 16. Global Imipenem and Cilastatin Injection Revenue by Clinical Indication (2021-2026) & ($ million)
Table 17. Global Imipenem and Cilastatin Injection Revenue Market Share by Clinical Indication (2021-2026)
Table 18. Global Imipenem and Cilastatin Injection Sale Price by Clinical Indication (2021-2026) & (US$/Unit)
Table 19. Global Imipenem and Cilastatin Injection Sale by Application (2021-2026) & (K Units)
Table 20. Global Imipenem and Cilastatin Injection Sale Market Share by Application (2021-2026)
Table 21. Global Imipenem and Cilastatin Injection Revenue by Application (2021-2026) & ($ million)
Table 22. Global Imipenem and Cilastatin Injection Revenue Market Share by Application (2021-2026)
Table 23. Global Imipenem and Cilastatin Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 24. Global Imipenem and Cilastatin Injection Sales by Company (2021-2026) & (K Units)
Table 25. Global Imipenem and Cilastatin Injection Sales Market Share by Company (2021-2026)
Table 26. Global Imipenem and Cilastatin Injection Revenue by Company (2021-2026) & ($ millions)
Table 27. Global Imipenem and Cilastatin Injection Revenue Market Share by Company (2021-2026)
Table 28. Global Imipenem and Cilastatin Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 29. Key Manufacturers Imipenem and Cilastatin Injection Producing Area Distribution and Sales Area
Table 30. Players Imipenem and Cilastatin Injection Products Offered
Table 31. Imipenem and Cilastatin Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 32. New Products and Potential Entrants
Table 33. Market M&A Activity & Strategy
Table 34. Global Imipenem and Cilastatin Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 35. Global Imipenem and Cilastatin Injection Sales Market Share Geographic Region (2021-2026)
Table 36. Global Imipenem and Cilastatin Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 37. Global Imipenem and Cilastatin Injection Revenue Market Share by Geographic Region (2021-2026)
Table 38. Global Imipenem and Cilastatin Injection Sales by Country/Region (2021-2026) & (K Units)
Table 39. Global Imipenem and Cilastatin Injection Sales Market Share by Country/Region (2021-2026)
Table 40. Global Imipenem and Cilastatin Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 41. Global Imipenem and Cilastatin Injection Revenue Market Share by Country/Region (2021-2026)
Table 42. Americas Imipenem and Cilastatin Injection Sales by Country (2021-2026) & (K Units)
Table 43. Americas Imipenem and Cilastatin Injection Sales Market Share by Country (2021-2026)
Table 44. Americas Imipenem and Cilastatin Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Americas Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 46. Americas Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 47. APAC Imipenem and Cilastatin Injection Sales by Region (2021-2026) & (K Units)
Table 48. APAC Imipenem and Cilastatin Injection Sales Market Share by Region (2021-2026)
Table 49. APAC Imipenem and Cilastatin Injection Revenue by Region (2021-2026) & ($ millions)
Table 50. APAC Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 51. APAC Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 52. Europe Imipenem and Cilastatin Injection Sales by Country (2021-2026) & (K Units)
Table 53. Europe Imipenem and Cilastatin Injection Revenue by Country (2021-2026) & ($ millions)
Table 54. Europe Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 55. Europe Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 56. Middle East & Africa Imipenem and Cilastatin Injection Sales by Country (2021-2026) & (K Units)
Table 57. Middle East & Africa Imipenem and Cilastatin Injection Revenue Market Share by Country (2021-2026)
Table 58. Middle East & Africa Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 59. Middle East & Africa Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Imipenem and Cilastatin Injection
Table 61. Key Market Challenges & Risks of Imipenem and Cilastatin Injection
Table 62. Key Industry Trends of Imipenem and Cilastatin Injection
Table 63. Imipenem and Cilastatin Injection Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Imipenem and Cilastatin Injection Distributors List
Table 66. Imipenem and Cilastatin Injection Customer List
Table 67. Global Imipenem and Cilastatin Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 68. Global Imipenem and Cilastatin Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Americas Imipenem and Cilastatin Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Americas Imipenem and Cilastatin Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. APAC Imipenem and Cilastatin Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 72. APAC Imipenem and Cilastatin Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 73. Europe Imipenem and Cilastatin Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 74. Europe Imipenem and Cilastatin Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. Middle East & Africa Imipenem and Cilastatin Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 76. Middle East & Africa Imipenem and Cilastatin Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. Global Imipenem and Cilastatin Injection Sales Forecast by Type (2027-2032) & (K Units)
Table 78. Global Imipenem and Cilastatin Injection Revenue Forecast by Type (2027-2032) & ($ millions)
Table 79. Global Imipenem and Cilastatin Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 80. Global Imipenem and Cilastatin Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 81. Merck Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Merck Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 83. Merck Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Merck Main Business
Table 85. Merck Latest Developments
Table 86. Fresenius Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. Fresenius Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 88. Fresenius Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Fresenius Main Business
Table 90. Fresenius Latest Developments
Table 91. Venus Remedies Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Venus Remedies Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 93. Venus Remedies Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Venus Remedies Main Business
Table 95. Venus Remedies Latest Developments
Table 96. Sun Pharmaceutical Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Sun Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 98. Sun Pharmaceutical Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Sun Pharmaceutical Main Business
Table 100. Sun Pharmaceutical Latest Developments
Table 101. JW Pharmaceutical Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. JW Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 103. JW Pharmaceutical Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. JW Pharmaceutical Main Business
Table 105. JW Pharmaceutical Latest Developments
Table 106. Taiwan Biotech Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Taiwan Biotech Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 108. Taiwan Biotech Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Taiwan Biotech Main Business
Table 110. Taiwan Biotech Latest Developments
Table 111. Zhuhai United Laboratories Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Zhuhai United Laboratories Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 113. Zhuhai United Laboratories Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Zhuhai United Laboratories Main Business
Table 115. Zhuhai United Laboratories Latest Developments
Table 116. Hanhui Pharmaceuticals Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 118. Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Hanhui Pharmaceuticals Main Business
Table 120. Hanhui Pharmaceuticals Latest Developments
Table 1. Imipenem and Cilastatin Injection Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Imipenem and Cilastatin Injection Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 0.5g
Table 4. Major Players of 1.0g
Table 5. Major Players of 2.0g
Table 6. Global Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 7. Global Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Table 8. Global Imipenem and Cilastatin Injection Revenue by Type (2021-2026) & ($ million)
Table 9. Global Imipenem and Cilastatin Injection Revenue Market Share by Type (2021-2026)
Table 10. Global Imipenem and Cilastatin Injection Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of Severe Hospital-acquired Infections
Table 12. Major Players of Multidrug-resistant Bacterial Infections
Table 13. Major Players of Others
Table 14. Global Imipenem and Cilastatin Injection Sales by Clinical Indication (2021-2026) & (K Units)
Table 15. Global Imipenem and Cilastatin Injection Sales Market Share by Clinical Indication (2021-2026)
Table 16. Global Imipenem and Cilastatin Injection Revenue by Clinical Indication (2021-2026) & ($ million)
Table 17. Global Imipenem and Cilastatin Injection Revenue Market Share by Clinical Indication (2021-2026)
Table 18. Global Imipenem and Cilastatin Injection Sale Price by Clinical Indication (2021-2026) & (US$/Unit)
Table 19. Global Imipenem and Cilastatin Injection Sale by Application (2021-2026) & (K Units)
Table 20. Global Imipenem and Cilastatin Injection Sale Market Share by Application (2021-2026)
Table 21. Global Imipenem and Cilastatin Injection Revenue by Application (2021-2026) & ($ million)
Table 22. Global Imipenem and Cilastatin Injection Revenue Market Share by Application (2021-2026)
Table 23. Global Imipenem and Cilastatin Injection Sale Price by Application (2021-2026) & (US$/Unit)
Table 24. Global Imipenem and Cilastatin Injection Sales by Company (2021-2026) & (K Units)
Table 25. Global Imipenem and Cilastatin Injection Sales Market Share by Company (2021-2026)
Table 26. Global Imipenem and Cilastatin Injection Revenue by Company (2021-2026) & ($ millions)
Table 27. Global Imipenem and Cilastatin Injection Revenue Market Share by Company (2021-2026)
Table 28. Global Imipenem and Cilastatin Injection Sale Price by Company (2021-2026) & (US$/Unit)
Table 29. Key Manufacturers Imipenem and Cilastatin Injection Producing Area Distribution and Sales Area
Table 30. Players Imipenem and Cilastatin Injection Products Offered
Table 31. Imipenem and Cilastatin Injection Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 32. New Products and Potential Entrants
Table 33. Market M&A Activity & Strategy
Table 34. Global Imipenem and Cilastatin Injection Sales by Geographic Region (2021-2026) & (K Units)
Table 35. Global Imipenem and Cilastatin Injection Sales Market Share Geographic Region (2021-2026)
Table 36. Global Imipenem and Cilastatin Injection Revenue by Geographic Region (2021-2026) & ($ millions)
Table 37. Global Imipenem and Cilastatin Injection Revenue Market Share by Geographic Region (2021-2026)
Table 38. Global Imipenem and Cilastatin Injection Sales by Country/Region (2021-2026) & (K Units)
Table 39. Global Imipenem and Cilastatin Injection Sales Market Share by Country/Region (2021-2026)
Table 40. Global Imipenem and Cilastatin Injection Revenue by Country/Region (2021-2026) & ($ millions)
Table 41. Global Imipenem and Cilastatin Injection Revenue Market Share by Country/Region (2021-2026)
Table 42. Americas Imipenem and Cilastatin Injection Sales by Country (2021-2026) & (K Units)
Table 43. Americas Imipenem and Cilastatin Injection Sales Market Share by Country (2021-2026)
Table 44. Americas Imipenem and Cilastatin Injection Revenue by Country (2021-2026) & ($ millions)
Table 45. Americas Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 46. Americas Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 47. APAC Imipenem and Cilastatin Injection Sales by Region (2021-2026) & (K Units)
Table 48. APAC Imipenem and Cilastatin Injection Sales Market Share by Region (2021-2026)
Table 49. APAC Imipenem and Cilastatin Injection Revenue by Region (2021-2026) & ($ millions)
Table 50. APAC Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 51. APAC Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 52. Europe Imipenem and Cilastatin Injection Sales by Country (2021-2026) & (K Units)
Table 53. Europe Imipenem and Cilastatin Injection Revenue by Country (2021-2026) & ($ millions)
Table 54. Europe Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 55. Europe Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 56. Middle East & Africa Imipenem and Cilastatin Injection Sales by Country (2021-2026) & (K Units)
Table 57. Middle East & Africa Imipenem and Cilastatin Injection Revenue Market Share by Country (2021-2026)
Table 58. Middle East & Africa Imipenem and Cilastatin Injection Sales by Type (2021-2026) & (K Units)
Table 59. Middle East & Africa Imipenem and Cilastatin Injection Sales by Application (2021-2026) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Imipenem and Cilastatin Injection
Table 61. Key Market Challenges & Risks of Imipenem and Cilastatin Injection
Table 62. Key Industry Trends of Imipenem and Cilastatin Injection
Table 63. Imipenem and Cilastatin Injection Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Imipenem and Cilastatin Injection Distributors List
Table 66. Imipenem and Cilastatin Injection Customer List
Table 67. Global Imipenem and Cilastatin Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 68. Global Imipenem and Cilastatin Injection Revenue Forecast by Region (2027-2032) & ($ millions)
Table 69. Americas Imipenem and Cilastatin Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Americas Imipenem and Cilastatin Injection Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. APAC Imipenem and Cilastatin Injection Sales Forecast by Region (2027-2032) & (K Units)
Table 72. APAC Imipenem and Cilastatin Injection Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 73. Europe Imipenem and Cilastatin Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 74. Europe Imipenem and Cilastatin Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 75. Middle East & Africa Imipenem and Cilastatin Injection Sales Forecast by Country (2027-2032) & (K Units)
Table 76. Middle East & Africa Imipenem and Cilastatin Injection Revenue Forecast by Country (2027-2032) & ($ millions)
Table 77. Global Imipenem and Cilastatin Injection Sales Forecast by Type (2027-2032) & (K Units)
Table 78. Global Imipenem and Cilastatin Injection Revenue Forecast by Type (2027-2032) & ($ millions)
Table 79. Global Imipenem and Cilastatin Injection Sales Forecast by Application (2027-2032) & (K Units)
Table 80. Global Imipenem and Cilastatin Injection Revenue Forecast by Application (2027-2032) & ($ millions)
Table 81. Merck Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Merck Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 83. Merck Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 84. Merck Main Business
Table 85. Merck Latest Developments
Table 86. Fresenius Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. Fresenius Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 88. Fresenius Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Fresenius Main Business
Table 90. Fresenius Latest Developments
Table 91. Venus Remedies Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Venus Remedies Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 93. Venus Remedies Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Venus Remedies Main Business
Table 95. Venus Remedies Latest Developments
Table 96. Sun Pharmaceutical Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Sun Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 98. Sun Pharmaceutical Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Sun Pharmaceutical Main Business
Table 100. Sun Pharmaceutical Latest Developments
Table 101. JW Pharmaceutical Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. JW Pharmaceutical Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 103. JW Pharmaceutical Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. JW Pharmaceutical Main Business
Table 105. JW Pharmaceutical Latest Developments
Table 106. Taiwan Biotech Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Taiwan Biotech Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 108. Taiwan Biotech Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Taiwan Biotech Main Business
Table 110. Taiwan Biotech Latest Developments
Table 111. Zhuhai United Laboratories Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Zhuhai United Laboratories Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 113. Zhuhai United Laboratories Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. Zhuhai United Laboratories Main Business
Table 115. Zhuhai United Laboratories Latest Developments
Table 116. Hanhui Pharmaceuticals Basic Information, Imipenem and Cilastatin Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Product Portfolios and Specifications
Table 118. Hanhui Pharmaceuticals Imipenem and Cilastatin Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Hanhui Pharmaceuticals Main Business
Table 120. Hanhui Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Imipenem and Cilastatin Injection
Figure 2. Imipenem and Cilastatin Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Imipenem and Cilastatin Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Imipenem and Cilastatin Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Imipenem and Cilastatin Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Imipenem and Cilastatin Injection Sales Market Share by Country/Region (2025)
Figure 10. Imipenem and Cilastatin Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 0.5g
Figure 12. Product Picture of 1.0g
Figure 13. Product Picture of 2.0g
Figure 14. Global Imipenem and Cilastatin Injection Sales Market Share by Type in 2026
Figure 15. Global Imipenem and Cilastatin Injection Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Severe Hospital-acquired Infections
Figure 17. Product Picture of Multidrug-resistant Bacterial Infections
Figure 18. Product Picture of Others
Figure 19. Global Imipenem and Cilastatin Injection Sales Market Share by Clinical Indication in 2026
Figure 20. Global Imipenem and Cilastatin Injection Revenue Market Share by Clinical Indication (2021-2026)
Figure 21. Imipenem and Cilastatin Injection Consumed in Hospital
Figure 22. Global Imipenem and Cilastatin Injection Market: Hospital (2021-2026) & (K Units)
Figure 23. Imipenem and Cilastatin Injection Consumed in Clinic
Figure 24. Global Imipenem and Cilastatin Injection Market: Clinic (2021-2026) & (K Units)
Figure 25. Imipenem and Cilastatin Injection Consumed in Others
Figure 26. Global Imipenem and Cilastatin Injection Market: Others (2021-2026) & (K Units)
Figure 27. Global Imipenem and Cilastatin Injection Sale Market Share by Application (2025)
Figure 28. Global Imipenem and Cilastatin Injection Revenue Market Share by Application in 2026
Figure 29. Imipenem and Cilastatin Injection Sales by Company in 2026 (K Units)
Figure 30. Global Imipenem and Cilastatin Injection Sales Market Share by Company in 2026
Figure 31. Imipenem and Cilastatin Injection Revenue by Company in 2026 ($ millions)
Figure 32. Global Imipenem and Cilastatin Injection Revenue Market Share by Company in 2026
Figure 33. Global Imipenem and Cilastatin Injection Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global Imipenem and Cilastatin Injection Revenue Market Share by Geographic Region in 2026
Figure 35. Americas Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 36. Americas Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 37. APAC Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 38. APAC Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 39. Europe Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 40. Europe Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 43. Americas Imipenem and Cilastatin Injection Sales Market Share by Country in 2026
Figure 44. Americas Imipenem and Cilastatin Injection Revenue Market Share by Country (2021-2026)
Figure 45. Americas Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 46. Americas Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 47. United States Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC Imipenem and Cilastatin Injection Sales Market Share by Region in 2026
Figure 52. APAC Imipenem and Cilastatin Injection Revenue Market Share by Region (2021-2026)
Figure 53. APAC Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 54. APAC Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 55. China Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 59. India Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe Imipenem and Cilastatin Injection Sales Market Share by Country in 2026
Figure 63. Europe Imipenem and Cilastatin Injection Revenue Market Share by Country (2021-2026)
Figure 64. Europe Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 65. Europe Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 66. Germany Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 67. France Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 68. UK Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa Imipenem and Cilastatin Injection Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 74. Egypt Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Imipenem and Cilastatin Injection in 2026
Figure 80. Manufacturing Process Analysis of Imipenem and Cilastatin Injection
Figure 81. Industry Chain Structure of Imipenem and Cilastatin Injection
Figure 82. Channels of Distribution
Figure 83. Global Imipenem and Cilastatin Injection Sales Market Forecast by Region (2027-2032)
Figure 84. Global Imipenem and Cilastatin Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global Imipenem and Cilastatin Injection Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global Imipenem and Cilastatin Injection Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global Imipenem and Cilastatin Injection Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global Imipenem and Cilastatin Injection Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Imipenem and Cilastatin Injection
Figure 2. Imipenem and Cilastatin Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Imipenem and Cilastatin Injection Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Imipenem and Cilastatin Injection Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Imipenem and Cilastatin Injection Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Imipenem and Cilastatin Injection Sales Market Share by Country/Region (2025)
Figure 10. Imipenem and Cilastatin Injection Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 0.5g
Figure 12. Product Picture of 1.0g
Figure 13. Product Picture of 2.0g
Figure 14. Global Imipenem and Cilastatin Injection Sales Market Share by Type in 2026
Figure 15. Global Imipenem and Cilastatin Injection Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of Severe Hospital-acquired Infections
Figure 17. Product Picture of Multidrug-resistant Bacterial Infections
Figure 18. Product Picture of Others
Figure 19. Global Imipenem and Cilastatin Injection Sales Market Share by Clinical Indication in 2026
Figure 20. Global Imipenem and Cilastatin Injection Revenue Market Share by Clinical Indication (2021-2026)
Figure 21. Imipenem and Cilastatin Injection Consumed in Hospital
Figure 22. Global Imipenem and Cilastatin Injection Market: Hospital (2021-2026) & (K Units)
Figure 23. Imipenem and Cilastatin Injection Consumed in Clinic
Figure 24. Global Imipenem and Cilastatin Injection Market: Clinic (2021-2026) & (K Units)
Figure 25. Imipenem and Cilastatin Injection Consumed in Others
Figure 26. Global Imipenem and Cilastatin Injection Market: Others (2021-2026) & (K Units)
Figure 27. Global Imipenem and Cilastatin Injection Sale Market Share by Application (2025)
Figure 28. Global Imipenem and Cilastatin Injection Revenue Market Share by Application in 2026
Figure 29. Imipenem and Cilastatin Injection Sales by Company in 2026 (K Units)
Figure 30. Global Imipenem and Cilastatin Injection Sales Market Share by Company in 2026
Figure 31. Imipenem and Cilastatin Injection Revenue by Company in 2026 ($ millions)
Figure 32. Global Imipenem and Cilastatin Injection Revenue Market Share by Company in 2026
Figure 33. Global Imipenem and Cilastatin Injection Sales Market Share by Geographic Region (2021-2026)
Figure 34. Global Imipenem and Cilastatin Injection Revenue Market Share by Geographic Region in 2026
Figure 35. Americas Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 36. Americas Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 37. APAC Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 38. APAC Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 39. Europe Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 40. Europe Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 41. Middle East & Africa Imipenem and Cilastatin Injection Sales 2021-2026 (K Units)
Figure 42. Middle East & Africa Imipenem and Cilastatin Injection Revenue 2021-2026 ($ millions)
Figure 43. Americas Imipenem and Cilastatin Injection Sales Market Share by Country in 2026
Figure 44. Americas Imipenem and Cilastatin Injection Revenue Market Share by Country (2021-2026)
Figure 45. Americas Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 46. Americas Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 47. United States Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 48. Canada Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 49. Mexico Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 50. Brazil Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 51. APAC Imipenem and Cilastatin Injection Sales Market Share by Region in 2026
Figure 52. APAC Imipenem and Cilastatin Injection Revenue Market Share by Region (2021-2026)
Figure 53. APAC Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 54. APAC Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 55. China Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 56. Japan Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 57. South Korea Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 58. Southeast Asia Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 59. India Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 60. Australia Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 61. China Taiwan Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 62. Europe Imipenem and Cilastatin Injection Sales Market Share by Country in 2026
Figure 63. Europe Imipenem and Cilastatin Injection Revenue Market Share by Country (2021-2026)
Figure 64. Europe Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 65. Europe Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 66. Germany Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 67. France Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 68. UK Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 69. Italy Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 70. Russia Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 71. Middle East & Africa Imipenem and Cilastatin Injection Sales Market Share by Country (2021-2026)
Figure 72. Middle East & Africa Imipenem and Cilastatin Injection Sales Market Share by Type (2021-2026)
Figure 73. Middle East & Africa Imipenem and Cilastatin Injection Sales Market Share by Application (2021-2026)
Figure 74. Egypt Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 75. South Africa Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 76. Israel Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 77. Turkey Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 78. GCC Countries Imipenem and Cilastatin Injection Revenue Growth 2021-2026 ($ millions)
Figure 79. Manufacturing Cost Structure Analysis of Imipenem and Cilastatin Injection in 2026
Figure 80. Manufacturing Process Analysis of Imipenem and Cilastatin Injection
Figure 81. Industry Chain Structure of Imipenem and Cilastatin Injection
Figure 82. Channels of Distribution
Figure 83. Global Imipenem and Cilastatin Injection Sales Market Forecast by Region (2027-2032)
Figure 84. Global Imipenem and Cilastatin Injection Revenue Market Share Forecast by Region (2027-2032)
Figure 85. Global Imipenem and Cilastatin Injection Sales Market Share Forecast by Type (2027-2032)
Figure 86. Global Imipenem and Cilastatin Injection Revenue Market Share Forecast by Type (2027-2032)
Figure 87. Global Imipenem and Cilastatin Injection Sales Market Share Forecast by Application (2027-2032)
Figure 88. Global Imipenem and Cilastatin Injection Revenue Market Share Forecast by Application (2027-2032)
